Gilead Sciences (NASDAQ:GILD) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Key Points

• Gilead beat quarterly expectations: Non-GAAP EPS was $2.55 versus the $2.19 consensus, while revenue reached $8.30 billion, up 6.8% year over year and above the $7.80 billion estimate.
• HIV portfolio drove growth: HIV sales increased 18%, with Biktarvy reaching a record 53% U.S. treatment share. Gilead raised its full-year product-sales forecast to $31.0 billion–$31.3 billion.
• Risks remain: CMS pricing for Biktarvy could reduce Gilead’s 2028 net revenue by roughly $1.5 billion, while cell-therapy sales fell 18% and clinical trials for KITE-753 remain partially on hold.

Gilead Sciences (NASDAQ:GILD - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts' consensus estimates of $2.19 by $0.36, FiscalAI reports. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company's revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.47 earnings per share.

Here are the key takeaways from Gilead Sciences' conference call:

• Strong third-quarter execution: Base business sales rose 16% year over year to $8.2 billion, led by HIV products, TRODELVY, and Livdelzi. Gilead raised its 2026 base-business revenue guidance by $900 million at the midpoint.
• HIV momentum remained robust, with sales up 18% and BIKTARVY reaching a record 53% U.S. treatment share. Yeztugo sales reached $305 million for the quarter and are tracking toward approximately $1 billion for the full year, while the Bixlenvo launch is reportedly progressing ahead of comparable launches.
• The company highlighted a broadening growth pipeline, including a potential 2027 filing for once-weekly oral HIV treatment, additional long-acting HIV options, seven clinical-stage oncology ADC programs, and 13 inflammation programs. Management also expects a potential anito-cel approval in December for relapsed or refractory multiple myeloma.
• CMS set BIKTARVY’s Medicare price at $2,600 per 30-day supply, approximately 38% below list price. Gilead preliminarily estimates a roughly $1.5 billion net revenue impact in 2028, including spillover effects across Medicaid, 340B, and other U.S. channels.
• Cell therapy sales declined 18% year over year because of competitive pressure, and the PALISADES-1 and -2 studies of KITE-753 are on partial clinical hold while the company investigates higher-grade ICANS differences between trial phases. Gilead said there were no patient deaths but paused the studies pending further review.

Gilead Sciences Price Performance

GILD stock traded up $6.41 during trading on Thursday, hitting $165.61. 8,397,874 shares of the company traded hands, compared to its average volume of 5,751,038. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences has a 1 year low of $114.02 and a 1 year high of $165.70. The stock's 50-day simple moving average is $150.33 and its 200 day simple moving average is $139.55.

Analyst Ratings Changes

Several brokerages have commented on GILD. Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 8th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a report on Saturday, September 19th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $165.00 to $163.00 and set an "overweight" rating for the company in a report on Wednesday, October 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $159.81.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider owned 113,684 shares in the company, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company's stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is currently owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported non-GAAP earnings of $2.55 per share, beating analysts’ $2.19 estimate by $0.36. Quarterly revenue reached $8.30 billion, exceeding expectations by approximately $500 million. Gilead Sciences Non-GAAP EPS and Revenue Beat
• Positive Sentiment: The company raised its full-year product-sales forecast to $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, citing continued momentum across its HIV portfolio. Biktarvy remains the primary growth driver. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: Gilead completed negotiations for Canadian reimbursement of Lyvdelzi, its liver-disease treatment. Broader reimbursement access could support the drug’s commercial rollout and provide an additional growth opportunity. Gilead Reaches Canadian Reimbursement Deal for Lyvdelzi
• Neutral Sentiment: Robert W. Baird maintained a Hold rating, suggesting the earnings strength is balanced by questions about growth outside the HIV franchise. Gilead Sciences Gets a Hold from Robert W. Baird
• Negative Sentiment: Analyst commentary indicates that Gilead’s non-HIV businesses remain a work in progress, while some coverage has highlighted continued cash usage. These issues could limit valuation expansion if the company cannot diversify growth beyond Biktarvy and its broader HIV portfolio. Gilead’s HIV Franchise Powers Earnings Beat

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.